The impact of co-circulating pathogens on SARS-CoV-2/COVID-19 surveillance: How concurrent epidemics may decrease true SARS-CoV-2 percent positivity
View ORCID ProfileAleksandra Kovacevic, View ORCID ProfileRosalind M. Eggo, View ORCID ProfileMarc Baguelin, View ORCID ProfileMatthieu Domenech de Cellès, View ORCID ProfileLulla Opatowski
doi: https://doi.org/10.1101/2021.06.08.21258533
Aleksandra Kovacevic
1Epidemiology and Modelling of Antibiotic Evasion Unit, Institut Pasteur, 25 rue du docteur Roux, Paris 75015, France
2Anti-infective Evasion and Pharmacoepidemiology Team, CESP, Université Paris-Saclay, UVSQ, INSERM U1018 Montigny-le-Bretonneux, France
Rosalind M. Eggo
3Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK
Marc Baguelin
4Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
5MRC Centre for Global Infectious Disease Analysis and the Department of Infectious Disease Epidemiology, Imperial College London, London, UK
Matthieu Domenech de Cellès
6Max Planck Institute for Infection Biology, Infectious Disease Epidemiology group, Charitéplatz 1, Campus Charité Mitte, 10117 Berlin, Germany
Lulla Opatowski
1Epidemiology and Modelling of Antibiotic Evasion Unit, Institut Pasteur, 25 rue du docteur Roux, Paris 75015, France
2Anti-infective Evasion and Pharmacoepidemiology Team, CESP, Université Paris-Saclay, UVSQ, INSERM U1018 Montigny-le-Bretonneux, France
Article usage
Posted June 12, 2021.
The impact of co-circulating pathogens on SARS-CoV-2/COVID-19 surveillance: How concurrent epidemics may decrease true SARS-CoV-2 percent positivity
Aleksandra Kovacevic, Rosalind M. Eggo, Marc Baguelin, Matthieu Domenech de Cellès, Lulla Opatowski
medRxiv 2021.06.08.21258533; doi: https://doi.org/10.1101/2021.06.08.21258533
The impact of co-circulating pathogens on SARS-CoV-2/COVID-19 surveillance: How concurrent epidemics may decrease true SARS-CoV-2 percent positivity
Aleksandra Kovacevic, Rosalind M. Eggo, Marc Baguelin, Matthieu Domenech de Cellès, Lulla Opatowski
medRxiv 2021.06.08.21258533; doi: https://doi.org/10.1101/2021.06.08.21258533
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (200)
- Cardiovascular Medicine (2914)
- Dermatology (249)
- Emergency Medicine (438)
- Epidemiology (12704)
- Forensic Medicine (12)
- Gastroenterology (826)
- Genetic and Genomic Medicine (4563)
- Geriatric Medicine (414)
- Health Economics (724)
- Health Informatics (2910)
- Health Policy (1068)
- Hematology (385)
- HIV/AIDS (921)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4327)
- Nursing (234)
- Nutrition (636)
- Oncology (2259)
- Ophthalmology (642)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (278)
- Palliative Medicine (83)
- Pathology (496)
- Pediatrics (1196)
- Primary Care Research (494)
- Public and Global Health (6912)
- Radiology and Imaging (1522)
- Respiratory Medicine (914)
- Rheumatology (436)
- Sports Medicine (382)
- Surgery (484)
- Toxicology (60)
- Transplantation (210)
- Urology (178)